Bristol-Myers Squibb is a global biopharmaceutical company focused on oncology, hematology, immunology, cardiovascular disease, and neuroscience. Its growth portfolio includes cancer immunotherapy Opdivo and its subcutaneous formulation, Reblozyl for anemia, CAR-T cell therapies Breyanzi and Abecma, Camzyos for cardiomyopathy, Sotyktu for psoriasis, and Cobenfy, the first new mechanism for schizophrenia in decades, acquired with Karuna Therapeutics. These are offsetting steep patent-cliff declines in legacy blockbusters Revlimid, Eliquis (partnered with Pfizer), Sprycel, and Pomalyst. The 2019 Celgene acquisition made BMS a hematology leader and brought much of its current pipeline. The company traces its roots to 1858 and 1887 predecessor firms merged in 1989, and is headquartered in Princeton, New Jersey.

Piotroski F-Score

Beneish M-Score

Operating Margin %

PE Ratio

Revenue per Share

Insider Sell

Price

PS Ratio

Dividend Yield %

Altman Z-Score

Bristol-Myers Squibb Co